Milestone Pharma hits record low after FDA declines to approve heart rhythm nasal spray
Shares of drug developer Milestone Pharmaceuticals MIST.O fall as much as 66.7% to record low of 75 cents
Stock down 59% at 92 cents in afternoon trade
US FDA declined to approve MIST's nasal spray, Cardamyst, to treat a type of heart condition, company says
FDA raised no concerns about clinical safety or efficacy, but highlighted two key chemistry, manufacturing and controls issues - MIST
Issues include needing additional information on nitrosamine impurities, cancer-causing compounds formed during manufacturing and an inspection of a testing facility
Including session moves, stock down 60% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Nvidia Stock: Breaking Down Its Key Risk and Why It’s Still a Compelling Buy in 2026

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?

Tradingkey






